261
Participants
Start Date
October 31, 2008
Primary Completion Date
January 31, 2010
Study Completion Date
January 31, 2010
placebo
subcutaneous injection, twice a day
exenatide
subcutaneous injection, twice a day, 10mcg
Research Site, Peoria
Research Site, Phoenix
Research Site, Buena Park
Research Site, Concord
Research Site, Fresno
Research Site, Greenbrae
Research Site, La Mesa
Research Site, Lancaster
Research Site, Northridge
Research Site, Palm Springs
Research Site, Salinas
Research Site, Hollywood
Research Site, Jacksonville
Research Site, Atlanta
Research Site, Honolulu
Research Site, Idaho Falls
Research Site, Des Moines
Research Site, Wichita
Research Site, Baton Rouge
Research Site, Lafayette
Research Site, Matairie
Research Site, Boston
Research Site, Minneapolis
Research Site, Chesterfield
Research Site, St Louis
Research Site, Omaha
Research Site, Las Vegas
Research Site, Berkeley Heights
Research SIte, Teaneck
Research Site, Albuquerque
Research SIte, New York
Research Site, Durham
Research Site, Bend
Research Site, Dallas
Research Site, El Paso
Research Site, Georgetown
Research Site, San Antonio
Research Site, Richmond
Research Site, Vancouver
Research Site, Kenosha
Research Site, Athens
Research Site, Thessaloniki
Research Site, Holon
Research Site, Kfar Saba
Research Site, Tel Litwinsky
Research Site, Coatzacoalcos
Research Site, Monterrey
Research Site, México
Research Site, Carolina
Research Site, Hato Rey
Research Site, Ponce
Research Site, San Juan
Research Site, Birmingham
Research Site, Guildford
Research Site, Leicester
Research Site, Livingston
Research Site, Middlesbrough
Research Site, Swansea
Research Site, Torquay
Lead Sponsor
Eli Lilly and Company
INDUSTRY
AstraZeneca
INDUSTRY